Perrigo Feeds OTC Brand Play With Prevacid As GSK Thins Consumer Lineup

Already providing generic equivalents, Perrigo buys national brand from GSK as it acts on commitment to move into brand product sales. Plans to expand OTC Prevacid line, likely with an orally disintegrating tablet, and to grow entire US OTC gastrointestinal category.

Handshake of businessmen

Perrigo Co. PLC expects to offer Prevacid 24 HR in an orally disintegrating tablet following its purchase of the brand from GlaxoSmithKline PLC, its first deal since making a “nationally brand better” commitment.

For GSK, divesting US rights to Prevacid 24 HR leaves it with another proton pump inhibitor to treat for frequent heartburn in the consumer health portfolio under its control. The UK pharma will market Pfizer Inc

More from Business

More from Health